RBC Capital lowers Xylem price target to $135, keeps Outperform
- RBC Capital lowered Xylem's price target from $164 to $135
- Analyst Jeffrey Reive maintained an Outperform rating on the stock
- The revision reflects a updated valuation model for the water technology provider

*this image is generated using AI for illustrative purposes only.
Xylem Inc received a revised valuation assessment from RBC Capital, with the firm lowering its price target while maintaining a positive stance on the stock.
Analyst Jeffrey Reive reduced the price target from $164 to $135. Despite the downward adjustment in the target price, the brokerage retained its Outperform rating on the company, indicating continued confidence in the stock's relative performance potential.
What specific macroeconomic or sector-specific factors drove RBC Capital's 17% reduction in Xylem's price target?
How might the lowered price target influence institutional investor sentiment and trading volume for Xylem in the upcoming quarter?
Are other major brokerage firms expected to revise their valuations for Xylem following RBC's adjustment?

































